Key Takeaways
- • US growth equity funds raised a record $33.2bn in H1 2026, representing 36% year-over-year growth and the strongest first-half performance in the strategy's history, according to Preqin data cited by the Financial Times.
- • Fundraising activity concentrated among fewer managers, with 87 growth equity funds closing capital in H1 2026 versus 96 in the prior-year period, indicating increasing selectivity in institutional allocations to the strategy.
- • Attractive entry valuations following material declines from 2021 peaks, combined with renewed interest in artificial intelligence-focused investments, have reignited institutional demand for growth equity after a 2023 trough of $29bn in annual fundraising.
- • Growth equity capital raising trajectory has rebounded across 2024, 2025, and H1 2026 following a severe contraction triggered by pandemic-era valuation compression and a weak exit environment that constrained investor dry powder and LP commitments.
Summary
US growth private equity—targeting high-growth companies without control stakes—is experiencing a sharp fundraising revival, with managers raising $33.2bn in the first half of 2026, the strongest opening half in the strategy's history. The figure represents a 36% increase compared to H1 2025 and substantially outpaced broader private equity fundraising growth of 20% across other strategies, signaling particular institutional appetite for the growth equity segment.
The rebound is notable for occurring among a contracting manager base. Only 87 growth equity funds closed capital in H1 2026, down from 96 funds in H1 2025, underscoring a shift toward concentrated allocations among established and specialist managers. This selectivity reflects institutional investor discipline following the sector's turbulent post-pandemic period, when loose monetary policy and abundant capital fueled a technology investment boom that exposed fundamental challenges in converting rapid revenue growth into sustainable profitability.
Growth equity fundraising peaked at $67bn for full-year 2021 during the pandemic-era technology surge. However, tightening financial conditions and deteriorating exit environments—characterized by collapsed IPO activity and reduced M&A transactions—devastated fundraising momentum. The strategy contracted sharply to $29bn in 2023 as investors reassessed risk-return profiles and LP commitments declined. The weak exit environment compounded pressure by limiting cash repatriation from existing portfolio investments, reducing institutional investors' capacity to commit capital to new funds.
The current recovery reflects two critical market developments. First, private company valuations have declined materially from 2021 peaks, creating attractive entry multiples for new growth equity deployments. Second, institutional investors have renewed interest in artificial intelligence-focused investment opportunities within the growth equity segment. These factors, combined with modest stabilization in exit markets and gradual capital availability among LP bases, have enabled the strategy to stage consecutive years of recovery beginning in 2024. Current fundraising trajectory suggests H1 2026's record-setting pace will extend into full-year 2026 performance.
The rebound is notable for occurring among a contracting manager base. Only 87 growth equity funds closed capital in H1 2026, down from 96 funds in H1 2025, underscoring a shift toward concentrated allocations among established and specialist managers. This selectivity reflects institutional investor discipline following the sector's turbulent post-pandemic period, when loose monetary policy and abundant capital fueled a technology investment boom that exposed fundamental challenges in converting rapid revenue growth into sustainable profitability.
Growth equity fundraising peaked at $67bn for full-year 2021 during the pandemic-era technology surge. However, tightening financial conditions and deteriorating exit environments—characterized by collapsed IPO activity and reduced M&A transactions—devastated fundraising momentum. The strategy contracted sharply to $29bn in 2023 as investors reassessed risk-return profiles and LP commitments declined. The weak exit environment compounded pressure by limiting cash repatriation from existing portfolio investments, reducing institutional investors' capacity to commit capital to new funds.
The current recovery reflects two critical market developments. First, private company valuations have declined materially from 2021 peaks, creating attractive entry multiples for new growth equity deployments. Second, institutional investors have renewed interest in artificial intelligence-focused investment opportunities within the growth equity segment. These factors, combined with modest stabilization in exit markets and gradual capital availability among LP bases, have enabled the strategy to stage consecutive years of recovery beginning in 2024. Current fundraising trajectory suggests H1 2026's record-setting pace will extend into full-year 2026 performance.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.